Rockwell Medical Q2 sales rise 11% on new customers

Rockwell Medical

13/08/2026 11:13

Overview
Hemodialysis products maker's Q2 net sales rose 11% yr/yr, driven by new customer growth
Gross profit up 30% yr/yr as gross margin expands to 18% on lower manufacturing costs, higher volume
Company completed 1-for-10 reverse stock split in July to regain Nasdaq compliance

Outlook
Rockwell Medical sees 2026 net sales of $70 mln to $75 mln
Company expects 2026 gross margin of 18% to 22%
Rockwell Medical forecasts 2026 adjusted EBITDA of $1 mln to $2 mln

Result Drivers
NEW CUSTOMERS AND HIGHER VOLUME - Co said Q2 net sales rose mainly due to additional sales to new customers in the Western US and greater purchasing from existing customers
LOWER MANUFACTURING COSTS - Co attributed 30% yr/yr increase in Q2 gross profit and margin expansion to lower manufacturing costs and higher volume
OPERATIONAL EFFICIENCY INITIATIVES - Co said it is streamlining and enhancing operational efficiencies and distribution footprint to generate additional savings

Company press release: ID:nBw9SBNbFa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Slight Miss*
$17.80 mln
$17.84 mln (2 Analysts)
Q2 Loss Per Share
 
$0.34
 
Q2 Net Loss
 
$1.20 mln
 
Q2 Gross Profit
 
$3.20 mln
 
Q2 Operating Income
 
-$1.10 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Rockwell Medical Inc is $30.00, about 299.5% above its August 12 closing price of $7.51

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 12 - Humacyte Q2 net loss widens on inventory, production costs 
Aug 11 - Cardinal Health forecasts full-year profit above estimates on specialty drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)